Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intravitreal Bevacizumab for Neovascular Glaucoma (IVB NVG)

This study has been completed.
Information provided by:
Shahid Beheshti University of Medical Sciences Identifier:
First received: October 4, 2006
Last updated: February 14, 2008
Last verified: February 2008

October 4, 2006
February 14, 2008
April 2006
Not Provided
  • Change in intraocular pressure [ Time Frame: 6 months ]
  • Change in extent of iris neovascularization [ Time Frame: 6 months ]
Not Provided
Complete list of historical versions of study NCT00384631 on Archive Site
Best corrected visual acuity [ Time Frame: 6 months ]
Not Provided
Not Provided
Not Provided
Intravitreal Bevacizumab for Neovascular Glaucoma
Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial
Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Treatment
  • Neovascular
  • Glaucoma
  • Other: subconjunctival normal saline
    0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
  • Drug: Avastin
    intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
  • Sham Comparator: 2
    Intervention: Other: subconjunctival normal saline
  • Experimental: 1
    Intervention: Drug: Avastin
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2007
Not Provided

Inclusion Criteria:

  • Clinical diagnosis of NVG
  • Vision less than 20/200
  • age 10-80 years

Exclusion Criteria:

  • Uncontrolled Blood Pressure
  • History of thromboembolism
  • Congestive Heart Failure
  • Renal Failure
  • Pregnancy or Lactation
  • Active ocular or periocular infection
  • No light perception
Sexes Eligible for Study: All
10 Years to 80 Years   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
Not Provided
Not Provided
Not Provided
Not Provided
Shahid Beheshti University of Medical Sciences
Not Provided
Principal Investigator: Shahin Yazdani, MD Ophthalmic Research Center, Shaheed Beheshti Medical University
Shahid Beheshti University of Medical Sciences
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP